» Articles » PMID: 32014051

Genetic and Histologic Spatiotemporal Evolution of Recurrent, Multifocal, Multicentric and Metastatic Glioblastoma

Overview
Publisher Biomed Central
Specialty Neurology
Date 2020 Feb 5
PMID 32014051
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma is the most frequent and aggressive primary brain tumor, characterized by extensive brain invasion and rarely, systemic metastases. The pathogenesis of metastatic glioblastoma is largely unknown. We present the first integrated clinical/histologic/genetic analysis of 5 distinct brain and lung foci from a unique case of recurrent, multifocal, multicentric and metastatic glioblastoma. The initial right frontotemporal gliosarcoma received standard surgical/chemoradiation therapy and recurred 1.5 years later, co-occurring with three additional masses localized to the ipsilateral temporal lobe, cerebellum and lung. Synchronous metastatic lung carcinoma was suspected in this long-term smoker patient with family history of cancer. However, glioblastoma was confirmed in all tumors, although with different morphologic patterns, including ependymomatous and epithelioid. Genomic profiling revealed a germline FANCD2 variant of unknown significance, and a 4-gene somatic mutation signature shared by all tumors, consisting of TERT promoter and PTEN, RB1 and TP53 tumor suppressor mutations. Additional GRIN2A and ATM heterozygous mutations were selected in the cerebellar and lung foci, but were variably present in the supratentorial foci, indicating reduced post-therapeutic genetic evolution in brain foci despite morphologic variability. Significant genetic drift characterized the lung metastasis, likely explaining the known resistance of circulating glioblastoma cells to systemic seeding. MET overexpression was detected in the initial gliosarcoma and lung metastasis, possibly contributing to invasiveness. This comprehensive analysis sheds light on the temporospatial evolution of glioblastoma and underscores the importance of genetic testing for diagnosis and personalized therapy.

Citing Articles

Adult glioblastoma with Lynch syndrome-associated mismatch repair deficiency forms a distinct high-risk molecular subgroup.

Georgescu M Free Neuropathol. 2025; 5():32.

PMID: 39835141 PMC: 11745196. DOI: 10.17879/freeneuropathology-2024-5892.


Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated.

McDonald M, Gopakumar S, Juratli T, Eyupoglu I, Rao G, Mandel J Acta Neuropathol Commun. 2025; 13(1):9.

PMID: 39815367 PMC: 11737192. DOI: 10.1186/s40478-024-01900-1.


The prognostic significance of synchronous metastasis in glioblastoma multiforme patients: a propensity score-matched analysis using SEER data.

Shen H, Mei Q, Chai X, Jiang Y, Liu A, Liu J Front Neurol. 2024; 15:1429826.

PMID: 39440248 PMC: 11493671. DOI: 10.3389/fneur.2024.1429826.


Metastatic glioblastoma to the lungs: a case report and literature review.

Yuen C, Pekmezci M, Bao S, Kong X CNS Oncol. 2024; 13(1):2351789.

PMID: 38864820 PMC: 11172249. DOI: 10.1080/20450907.2024.2351789.


An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile.

Sato Y, Deguchi S, Norose T, Oishi T, Mitsuya K, Sugino T Nagoya J Med Sci. 2023; 85(4):828-835.

PMID: 38155632 PMC: 10751501. DOI: 10.18999/nagjms.85.4.828.


References
1.
Lun M, Lok E, Gautam S, Wu E, Wong E . The natural history of extracranial metastasis from glioblastoma multiforme. J Neurooncol. 2011; 105(2):261-73. DOI: 10.1007/s11060-011-0575-8. View

2.
Georgescu M, Li Y, Islam M, Notarianni C, Sun H, Olar A . Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications. Oncotarget. 2019; 10(40):4038-4052. PMC: 6592288. DOI: 10.18632/oncotarget.27005. View

3.
Molina J, Hayashi Y, Stephens C, Georgescu M . Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia. 2010; 12(6):453-63. PMC: 2887086. DOI: 10.1593/neo.10126. View

4.
Beauchesne P . Extra-neural metastases of malignant gliomas: myth or reality?. Cancers (Basel). 2013; 3(1):461-77. PMC: 3756372. DOI: 10.3390/cancers3010461. View

5.
Rebischung C, Gerard J, Gayet J, Thomas G, Hamelin R, Laurent-Puig P . Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer. 2002; 100(2):131-5. DOI: 10.1002/ijc.10480. View